Royalty Pharma (RPRX) EBITDA Margin Growth (3y) (2022 - 2026)
Powered by 
Analysis
Royalty Pharma (RPRX) EBITDA Margin Growth (3y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Orix | 44.91 Bn | 45.24 Bn | 4.68 Bn | 301.00 |
| 2 | Royalty Pharma | 36.78 Bn | 38.89 Bn | - | -2,649.00 |
| 3 | Royal Gold | 22.19 Bn | 22.06 Bn | 390.45 Mn | 1,222.00 |
| 4 | OR Royalties | 6.98 Bn | 6.91 Bn | 82.22 Mn | 3,929.00 |
| 5 | Encore Capital | 2.06 Bn | 1.88 Bn | 455.04 Mn | 1,073.00 |
| 6 | Atlanticus Holdings | 1.41 Bn | 853.17 Mn | 686.46 Mn | -134.00 |
| 7 | Jefferson Capital | 1.23 Bn | 1.21 Bn | - | - |
| 8 | Upbound | 1.11 Bn | 1.00 Bn | 594.84 Mn | -432.00 |
| 9 | Lufax Holding | 1.08 Bn | -1.19 Bn | - | -2,617.00 |
| 10 | Metalla Royalty & Streaming | 957.79 Mn | 946.72 Mn | 4.75 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2,649.00 |
| Mar 31, 2026 | 1,926.00 |
| Dec 31, 2025 | 14,775.00 |
| Sep 30, 2025 | 3,659.00 |
| Jun 30, 2025 | -3,423.00 |
| Mar 31, 2025 | 5,491.00 |
| Dec 31, 2024 | 3,425.00 |
| Sep 30, 2024 | 7,844.00 |
| Jun 30, 2024 | -8,405.00 |
| Mar 31, 2024 | -5,300.00 |
| Dec 31, 2023 | 4,793.00 |
| Sep 30, 2023 | -6,659.00 |
| Jun 30, 2023 | -3,388.00 |
| Mar 31, 2023 | -213.00 |
| Dec 31, 2022 | -37,645.00 |
| Sep 30, 2022 | -8,118.00 |
| Jun 30, 2022 | -116.00 |